Pending pivotal results, Novartis and Ophthotech alter Fovista agreement

10 July 2017
2019_biotech_test_vial_discovery_big

Swiss pharma giant  Novartis (NOVN: VX) and US biotech firm Ophthotech (Nasdaq: OPHT) have amended the terms of a  2014 agreement with respect to ophthalmic therapy Fovista (anti-PDGF aptamer).

The drug is being studied in combination with anti-VEGF agents for patients suffering from wet age-related macular degeneration (wet AMD).

According to a psoting on  Seeking Alpha, the new terms are a sign of a “mutual lack of confidence in a successful outcome of a Phase III clinical trial, OPH1004.” Results from the trial are expected later this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology